Bank Pictet & Cie Asia Ltd. Sells 3,950 Shares of Danaher Corporation (NYSE:DHR)

Bank Pictet & Cie Asia Ltd. trimmed its position in Danaher Corporation (NYSE:DHR) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,750 shares of the conglomerate’s stock after selling 3,950 shares during the quarter. Danaher accounts for approximately 1.0% of Bank Pictet & Cie Asia Ltd.’s portfolio, making the stock its 27th largest holding. Bank Pictet & Cie Asia Ltd.’s holdings in Danaher were worth $2,123,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. ETRADE Capital Management LLC grew its stake in Danaher by 5.1% during the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares in the last quarter. Honeywell International Inc. acquired a new stake in Danaher during the 2nd quarter valued at approximately $25,317,000. Roundview Capital LLC grew its stake in Danaher by 2.0% during the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares in the last quarter. Eastern Bank grew its stake in Danaher by 4,291.1% during the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock valued at $10,802,000 after purchasing an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co lifted its holdings in Danaher by 2.0% during the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock worth $2,484,000 after buying an additional 586 shares during the last quarter. Institutional investors own 76.32% of the company’s stock.

Several brokerages recently issued reports on DHR. Cowen reissued a “buy” rating and issued a $90.00 price target on shares of Danaher in a report on Wednesday, October 4th. J P Morgan Chase & Co restated an “overweight” rating and issued a $95.00 target price on shares of Danaher in a report on Friday, September 8th. Robert W. Baird lifted their price target on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Thursday, October 5th. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $83.00 price objective on shares of Danaher in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $93.31.

In other news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the transaction, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at $25,173,715.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. In the last three months, insiders sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is currently owned by company insiders.

Shares of Danaher Corporation (NYSE DHR) traded down $0.08 on Wednesday, hitting $92.74. The stock had a trading volume of 2,376,900 shares, compared to its average volume of 2,632,848. The firm has a market cap of $64,566.07, a P/E ratio of 23.86, a P/E/G ratio of 2.21 and a beta of 1.02. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Danaher Corporation has a fifty-two week low of $76.27 and a fifty-two week high of $94.82.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The firm had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the prior year, the business earned $0.87 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. sell-side analysts anticipate that Danaher Corporation will post 3.99 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s dividend payout ratio (DPR) is currently 16.52%.

COPYRIGHT VIOLATION WARNING: “Bank Pictet & Cie Asia Ltd. Sells 3,950 Shares of Danaher Corporation (NYSE:DHR)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/bank-pictet-cie-asia-ltd-sells-3950-shares-of-danaher-corporation-dhr.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply